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Abstract: This is a case report of a 83-year-old man with choroidal neovascularization (CNV), 
due to age-related macular degeneration (AMD) in his right eye. Digital ﬂ  uorescein (FA) and 
indocyanine green angiography (ICG) were performed, which disclosed predominantly classic 
subfoveal CNV and a dilated and tortuous feeding complex. The visual acuity was 20/800. 
Anti-vascular endothelial growth factor (anti-VEGF) treatment was suggested, however, the 
patient was not keen to receive an intraocular injection. Modiﬁ  ed photodynamic therapy (PDT) 
with spot size enlarged, to include not only the CNV lesion but the feeding complex as well, 
was performed. Ten days after one session of PDT, ICG showed absence of leakage from the 
CNV and complete occlusion of the feeding complex. The visual acuity gradually improved 
to 20/100 and remained stable during the following 23 months. No evidence of CNV leakage 
was seen in the FA and ICG during the follow up period. Adjustment of the PDT spot size to 
include the detectable by ICG feeding complex might be an additional option in order to close 
the subfoveal CNV and might be considered as an alternative to intravitreal injection of anti-
VEGF in selected cases where anti-VEGF treatment is not available.
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Introduction
Photodynamic therapy (PDT) has been used in the recent past years as an effective 
treatment to prevent signiﬁ  cant loss of vision in patients with choroidal neovascular-
ization (CNV) secondary to age-related macular degeneration (AMD) especially when 
the CNV is classic or predominantly classic.1,2
Previous studies demonstrated that 22%–44% of patients with CNV lesions 
have demonstrable feeder vessels.3 The concept of indocyanine green angiography 
(ICG)-guided feeder vessel photocoagulation has demonstrated favorable results in 
neovascular AMD.4–6
We report a favourable result with cessation of leakage of a subfoveal CNV in a 
patient with exudative AMD treated with a single session of PDT when the choroidal 
complex was included all along in the treatment spot.
Case report
An 83-year-old Caucasian man with history of diabetes mellitus, high blood pressure, 
and a nonsmoker was referred to us with the diagnosis of exudative maculopathy due 
to AMD in his right eye. His best corrected visual acuity (BCVA) of the right eye 
was 20/800.
The Topcon Imagenet 2000 Digital Imaging System with Imagenet 2000 (version 
2.14) software and the TRC-50IA fundus camera was used to perform ﬂ  uorescein Clinical Ophthalmology 2009:3 14
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(FA) and ICG angiography. FA angiography depicted a 
predominantly classic subfoveal CNV in the right eye of 
the patient (Figure 1). Further, ICG revealed a dilated and 
tortuous feeding complex of the CNV with prolonged course 
raised from the deeper choroidal layers ﬁ  lling early after dye 
administration (Figure 2).
Intravitreal anti-vascular endothelial growth factor 
(anti-VEGF) treatment was suggested to the patient, how-
ever, he adamantly refused to receive intraocular injections 
of any kind.
After a discussion underlining possible risks and beneﬁ  ts 
the patient decided to undergo photodynamic therapy instead 
of anti VEGF treatment. PDT was performed to treat the 
CNV according to the protocol of the treatment of AMD with 
PDT study.1,2 However the treatment spot size was enlarged 
to include in the treatment beam not only the CNV but also 
the feeding complex. Treatment was approved by the hospital 
Institutional Review Board.
Ten days after ﬁ  rst session of PDT, ICG showed cessation 
of leakage of the CNV with complete occlusion of the feeder 
vessel (Figure 3). BCVA improved to 20/200. The patient did 
not attend his three months follow up appointment, as recom-
mended. Six months post-PDT, FA and ICG (Figure 4A, B) 
showed cessation of the leakage of the previous subfoveal 
CNV. BCVA improved to 20/80. The FA and ICG images, as 
well as the BCVA remained stable up till today (23 months 
after PDT treatment).
Discussion
Anti-VEGF treatment has resulted in unprecedented visual 
and anatomic outcomes far outpacing other available 
treatments.7–9 Today physicians and patients can expect visual 
stabilization in most patients and visual improvement in 
many, particularly, if treatment is begun early in the course of 
the disease. PDT in combination with anti-VEGF have been 
also used for the treatment of CNV.10,11 However, similar to 
our patient, not all patients are happy to receive intraocular 
injections. Additionally, not all patients are able to afford 
the monthly treatment with anti-VEGF.
PDT has been proven to be beneﬁ  cial in reducing the risk 
of severe visual loss in selected patients with CNV caused by 
AMD. Randomised clinical trials of verteporﬁ  n therapy have 
demonstrated that an average of 3–4 retreatments are needed 
to control the CNV due to AMD in the ﬁ  rst year, decreasing 
to 2–3 in the second year. PDT provides temporary immediate 
occlusion of the CNV and absence of leakage in the FA after 
a single PDT.12 However studies with ICG have demonstrated 
in the great majority of cases the occlusion was not complete 
and the CNV remained open at least at the level of the feeder 
vessel. Schmidt-Erfurth and colleagues showed that feeder 
vessel occlusion after PDT is not complete and that the CNV 
complex remains patent at the level of FV in 50% of treated 
patients.3,12 Persistent feeder vessels were found to be the 
origin of newly developing neovascular proliferation.13
Occlusion of the feeder vessel, using modiﬁ  cations of 
the classic PDT treatment have been described in the recent 
years and the safety3 of extrafoveal PDT has been proven.3,4,14 
Piermarocchi and colleagues reported 16 eyes that received 
direct laser photocoagulation of the feeder vessel after 
PDT and did not need any further photodynamic therapy.4 
Staurenghi and colleagues reported favorable results in 
10 patients where the PDT was combined with feeder vessel 
laser treatment in comparison to those from 10 patients who 
Figure 1 Before PDT, ﬂ  uorescein angiography shows a predominantly classic 
subfoveal CNV.
Abbreviations: CNV, choroidal neovascularization; PDT, photodynamic therapy.
Figure 2 Before PDT, early-phase ICG illustrates a dilated and tortuous feeding 
complex (arrows) of the subfoveal CNV raised from a deeper choroidal layer.
Abbreviations: CNV, choroidal neovascularization; ICG, indocyanine green angiog-
raphy; PDT, photodynamic therapy.Clinical Ophthalmology 2009:3 15
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received treatment under the standard protocols of PDT.5 
Sickenberg and colleagues described two patients with AMD 
who, apart from the PDT, received complementary feeder 
vessel treatment.14 In the ﬁ  rst patient, the feeder vessel was 
occluded by minimal photocoagulation immediately after 
PDT treatment. The second patient was treated initially with 
a PDT spot covering the lesion, followed immediately by a 
small spot focused on the feeder vessel. In both cases sub-
foveal CNV was successfully occluded after PDT and some 
visual acuity was gained following the treatment.
In our patient, cessation of the leakage from the CNV 
was evident not only in the FA but also in the ICG, 10 days 
after a single session of PDT treatment when the feeding 
complex was included in the treatment spot. No evidence of 
recurrent CNV was seen in the FA or ICG during the follow 
up period. The visual acuity of our patient improved and 
remained unchanged for the following 23 months.
Of course, further research needs to be conducted in order 
to evaluate these ﬁ  ndings. Data from one patient can not 
establish a cause–effect relationship between treatment and 
clinical outcome. However, this case highlights the synergetic 
association of PDT with treatment modiﬁ  cations targeting 
the feeding complex of the CNV. The potential beneﬁ  t from 
a single PDT session with inclusion of the feeding complex 
in the PDT spot should be weighed against the detriment of 
treating a larger area of normal choroid and the effects of 
multiple PDT treatments to the normal choriocapillaries. The 
fact that PDT is a relatively inexpensive treatment modality 
should be also taken into consideration.
We have entered the era of anti-VEGF therapy in the 
treatment of CNV in patients with AMD. However in cases 
where anti-VEGF treatment is not available, an adjustment 
of the PDT spot size to include the detection by ICG feeding 
complex could be an additional option in the treatment of 
the subfoveal CNV and might be considered as an alterna-
tive treatment.
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